All In Biotech

Drug Trial Radar · NCT03272347

Islatravir (MK-8591) With Doravirine and Lamivudine in Participants Infected With Human Immunodeficiency Virus Type 1 (MK-8591-011)

A Phase 2B, Randomized, Double-Blind, Active-Comparator-Controlled, Dose-Ranging Clinical Trial to Evaluate the Safety, Tolerability, Antiretroviral Activity, and Pharmacokinetics of MK-8591 Given in Combination With Doravirine (DOR) and Lamivudine (3TC) in HIV-1-Infected Treatment-Naïve Adults

Last checked: Nov 19, 2026Latest source record: Mar 29, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 123 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

123

Actual

Start

Nov 27, 2017

Primary completion

Mar 8, 2021

Study completion Mar 9, 2022

Sponsor

Lead sponsor
Merck Sharp & Dohme LLCMerck & Co. (MRK)
Sponsor type
Industry
First posted
Sep 5, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will evaluate the safety, tolerability, antiretroviral activity, and pharmacokinetics of 3 doses of islatravir (MK-8591) in combination with doravirine (DOR) and lamivudine (3TC) administered to antiretroviral treatment-naïve adult participants with human immunodeficiency virus type 1 (HIV-1) infection.

Conditions

  • HIV-1 Infection

Interventions

  • IslatravirDrug

    Islatravir at 0.25 mg, 0.75 mg or 2.25 mg is orally administered QD in capsule form for up to 52 weeks. After Week 60 a selected open label dose may be administered.

  • Placebo to IslatravirDrug

    Placebo to islatravir is orally administered QD in capsule form for up to 52 weeks

  • DoravirineDrug

    Doravirine 100 mg is orally administered QD in tablet form for up to 144 weeks

  • Placebo to DoravirineDrug

    Placebo to Doravirine is orally administered QD in tablet form for up to 52 weeks

  • LamivudineDrug

    Lamivudine 300 mg is orally administered QD in tablet form for up to 52 weeks

  • Placebo to LamivudineDrug

    Placebo to Lamivudine is orally administered QD in tablet form for up to 52 weeks

  • Doravirine/Lamivudine/Tenofovir Disoproxil FumarateDrug

    Fixed dose combination of 100 mg doravirine + 300 mg lamivudine + 300 mg tenofovir disoproxil fumarate is orally administered QD in tablet form for up to 144 weeks.

  • Placebo to Doravirine/Lamivudine/Tenofovir Disoproxil FumarateDrug

    Placebo to doravirine/lamivudine/tenofovir disoproxil fumarate is orally administered QD in tablet form for up to 52 weeks

  • Doravirine/IslatravirDrug

    Fixed dose combination of islatravir 0.75 mg/doravirine 100 mg orally administered QD in tablet form for 48 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants With HIV-1 RNA <50 Copies/mL at Week 24Time frame: Week 24
  2. Percentage of Participants With HIV-1 RNA <50 Copies/mL at Week 48Time frame: Week 48
  3. Number of Participants Experiencing Adverse Events (AEs) up to Week 144Time frame: Up to 144 weeks
  4. Number of Participants Discontinuing Study Drug Due to AEs up to Week 144Time frame: Up to 144 weeks

Locations

26 sites in 4 countries. Site status is shown where the registry gives one.

  • Pueblo Family Physicians ( Site 0119)

    Phoenix, Arizona

  • University California / Davis ( Site 0101)

    Sacramento, California

  • Whitman Walker Clinic ( Site 0108)

    Washington D.C., District of Columbia

  • Orlando Immunology Center (OIC) ( Site 0105)

    Orlando, Florida

  • Northstar Medical Center ( Site 0102)

    Chicago, Illinois

  • Kansas City CARE Clinic ( Site 0106)

    Kansas City, Missouri

  • Saint Hope Foundation, Inc. ( Site 0116)

    Bellaire, Texas

  • North Texas Infectious Diseases Consultants, PA ( Site 0103)

    Dallas, Texas

  • Tarrant County Infectious Disease Associates ( Site 0112)

    Fort Worth, Texas

  • The Crofoot Research Center, Inc. ( Site 0118)

    Houston, Texas

  • Biomedica Research Group ( Site 0202)

    Santiago, Chile

  • Hospital Dr. Hernan Henriquez Aravena ( Site 0203)

    Temuco, Chile

  • Clinica Arauco Salud ( Site 0200)

    Santiago, RM, Chile

  • Hopital Avicenne ( Site 2302)

    Bobigny, France

  • Hopital Saint-Andre ( Site 2307)

    Bordeaux, France

  • CHU Hotel Dieu ( Site 2308)

    Nantes, France

  • CHU de Nice Hopital Archet 1 ( Site 2303)

    Nice, France

  • Hopital Bichat - Claude Bernard ( Site 2309)

    Paris, France

  • Hopital Pitie Salpetriere ( Site 2305)

    Paris, France

  • Hopital Saint Louis ( Site 2306)

    Paris, France

  • Centre Hospitalier de Tourcoing ( Site 2301)

    Tourcoing, France

  • Chelsea and Westminster Hospital ( Site 2101)

    London, United Kingdom

  • Royal London Hospital ( Site 2103)

    London, United Kingdom

  • The Royal Free London NHS Foundation Trust ( Site 2102)

    London, United Kingdom

  • North Manchester General Hospital ( Site 2104)

    Manchester, United Kingdom

  • Brighton and Sussex University Hospitals NHS Trust ( Site 2105)

    Brighton, East Sussex, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.